Acadia Pharmaceuticals Inc (ACAD)
Acadia Pharmaceuticals develops and sells medicines for neurological and rare diseases, including NUPLAZID and DAYBUE. It last closed at $18.32 on Nov 17, down 1.87% on the day. The average 12-month price target from 10 analysts is $32.20 (+75.8% from the last close), with a high of $38.00 and a low of $23.00. Analyst consensus is Strong Buy, based on the latest ratings from 10 firms (8 buy, 2 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $1.9M, the largest $1.3M.
Key Stats
Last 12 monthsNot reported for this period.
From ACAD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 10 analysts who set a price target on ACAD in the past 90 days. The average target is $32.20, with a high of $38.00 and a low of $23.00, compared with the last close of $18.32.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Morgan Stanley | Target lowered | Hold | $28 → $24 |
| Nov 6 | Canaccord Genuity | Target raised | Buy | $36 → $38 |
| Nov 5 | RBC Capital | Target raised | Buy | $37 → $38 |
| Oct 19 | Needham | Reiterated | Buy | $35 |
| Oct 13 | UBS | Downgrade | Hold | $49 → $23 |
Technical Analysis
The stock is 7% below its 20 day and 17% below its 50 day average. It is 27% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the Pivot at $18.31, and the nearest resistance the Pivot R1 at $18.68.
| RSI (14) | 39.92 | Weak, oversold below 30 | Neutral |
| MACD | -0.80 | Below its signal line | Bearish |
| Stochastic | 40.0 | Middle of its range | Neutral |
| ADX (14) | 32.4 | Trending down | |
| Williams %R | -63.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -92.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −10.9% | Change over 10 sessions | Bearish |
| ATR (14) | $1.02 | Typical daily range, 5.5% of price |
| RSI (14) | 34.97 | Weak, oversold below 30 | Neutral |
| MACD | -1.38 | Below its signal line | Bearish |
| Stochastic | 19.3 | Near the bottom of its range | Oversold |
| ADX (14) | 27.2 | Trending down | |
| Williams %R | -83.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -102.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −34.2% | Change over 10 sessions | Bearish |
| ATR (14) | $2.22 | Typical daily range, 12.1% of price |
What happened before
See how ACAD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ACAD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in ACAD in the last 90 days.
Dark Pool
30DACAD Institutional Ownership
Full report →- ▲201 buying vs 152 selling
- ▼Held by funds -1.3 pts
- ●Funds holding -2
- ▼Superinvestors: 1 added, 4 cut
- ▲Put/call 2.44 to 0.54
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 350 | 352 | −0.6% |
| In funds' top 10 | 4 | 5 | −20.0% |
| Held by funds | 96.4% | 97.7% | −1.3 pts |
| New / increased | 59 / 142 | 46 / 134 | +11.7% |
| Reduced / sold out | 90 / 62 | 110 / 36 | +4.1% |
| Put/call ratio | 0.54 | 2.44 | −77.9% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACAD is in one of them and how their past ACAD trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ACAD in an article yet. Here's the latest on the wider market.
ACAD Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Sell | $15K – $50K | Jul 29, 2026 | Sep 22, 2026 | 55 d |
| Christopher JacobsR · NY | Sell (partial) | $1K – $15K | Sep 8, 2020 | Nov 6, 2020 | 59 d |
| Gilbert CisnerosD · CA | Sell | $1K – $15K | Feb 19, 2019 | Mar 8, 2019 | 17 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Acadia Pharmaceuticals
Acadia Pharmaceuticals is a drug company based in San Diego, California, that develops and sells medicines for neurological and rare diseases. Its main commercial products are NUPLAZID, used for hallucinations and delusions linked to Parkinson's disease psychosis, and DAYBUE, used to treat Rett syndrome. The company also develops earlier-stage product candidates, including treatments for Alzheimer's disease psychosis. Its medicines are prescribed to patients, mainly in the United States.
- Headquarters
- San Diego, CA
- Founded
- 1993
- Website
- acadia-pharm.com ↗







